Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Stem Cell Research

  Free Subscription

Articles published in Leuk Lymphoma

Retrieve available abstracts of 162 articles:
HTML format

Single Articles

    July 2021
  1. ENSSLE JC, Wolf S, von Metzler I, Weber S, et al
    High CD34 positive stem cell dosage improves thrombocyte recovery in obese myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2021 Jul 13:1-5. doi: 10.1080/10428194.2021.1950707.

    June 2021
  2. CAMILLERI M, McGrath T, Wilson W, Ings SJ, et al
    Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients.
    Leuk Lymphoma. 2021 Jun 24:1-4. doi: 10.1080/10428194.2021.1941930.

  3. YOSHIMOTO G, Mori Y, Kato K, Odawara J, et al
    Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jun 23:1-10. doi: 10.1080/10428194.2021.1941937.
    PubMed     Abstract available

  4. HUSBY S, Favero F, Rodriguez-Gonzalez FG, Sutton LA, et al
    Mutations known from B-cell lymphoid malignancies are not found in CD34(+) stem cells from patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1933473.

  5. ZAMAGNI E, Dhanasiri S, Ghale A, Moore A, et al
    Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-b
    Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1924369.
    PubMed     Abstract available

    May 2021
  6. PASVOLSKY O, Shargian L, Rozovski U, Wolach O, et al
    Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation.
    Leuk Lymphoma. 2021 May 20:1-8. doi: 10.1080/10428194.2021.1929957.
    PubMed     Abstract available

  7. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.

  8. KUROSAWA S, Kaito S, Uchida N, Fukuda T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.
    Leuk Lymphoma. 2021 May 12:1-7. doi: 10.1080/10428194.2021.1924374.
    PubMed     Abstract available

    March 2021
  9. EPSTEIN-PETERSON ZD, Ganesan N, Barker JN, Drullinsky PR, et al
    Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
    Leuk Lymphoma. 2021 Mar 29:1-7. doi: 10.1080/10428194.2021.1897806.
    PubMed     Abstract available

  10. WENGE DV, Wethmar K, Mikesch JH, Reicherts C, et al
    Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.
    Leuk Lymphoma. 2021 Mar 29:1-10. doi: 10.1080/10428194.2021.1894645.
    PubMed     Abstract available

  11. CAZELLES C, Belhadj K, Vellemans H, Camus V, et al
    Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Leuk Lymphoma. 2021 Mar 25:1-8. doi: 10.1080/10428194.2021.1901090.
    PubMed     Abstract available

  12. FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
    Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Mar 21:1-3. doi: 10.1080/10428194.2021.1901097.

  13. SHEN Y, Qi J, Wang Y, Chen J, et al
    Hepatitis B immunoglobulin (HBIG) combined with long-term entecavir prophylaxis for hepatitis B virus infection in allogeneic hematopoietic stem cell transplantation with hepatitis B surface antigen-positive donors.
    Leuk Lymphoma. 2021 Mar 18:1-4. doi: 10.1080/10428194.2021.1901095.

    February 2021
  14. MODI D, Albanyan O, Kim S, Deol A, et al
    Grade 3-4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2021 Feb 24:1-11. doi: 10.1080/10428194.2021.1891231.
    PubMed     Abstract available

    January 2021
  15. PRABAHRAN A, Koldej R, Chee L, Wong E, et al
    Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jan 31:1-13. doi: 10.1080/10428194.2021.1872072.
    PubMed     Abstract available

  16. JAIME-PEREZ JC, Hernandez-Coronado M, Picon-Galindo E, Salazar-Cavazos L, et al
    Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning.
    Leuk Lymphoma. 2021 Jan 24:1-10. doi: 10.1080/10428194.2021.1876870.
    PubMed     Abstract available

    December 2020
  17. PLATE M, van Besien K
    Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2020 Dec 27:1-3. doi: 10.1080/10428194.2020.1864357.

  18. MORIGI A, Casadei B, Argnani L, Stefoni V, et al
    Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-3. doi: 10.1080/10428194.2020.1855342.

    November 2020
  19. VOCKOVA P, Molinsky J, Klanova M, Karban J, et al
    CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.
    Leuk Lymphoma. 2020 Nov 25:1-8. doi: 10.1080/10428194.2020.1849678.
    PubMed     Abstract available

  20. RASOR B, Dickerson T, Zhao Q, Elder P, et al
    Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
    Leuk Lymphoma. 2020 Nov 24:1-10. doi: 10.1080/10428194.2020.1849677.
    PubMed     Abstract available

  21. WANG T, Zhou B, Zhang J, Zhang X, et al
    Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
    Leuk Lymphoma. 2020 Nov 16:1-4. doi: 10.1080/10428194.2020.1846736.
    PubMed     Abstract available

  22. FU W, Huang A, Lu G, Ni X, et al
    Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission.
    Leuk Lymphoma. 2020 Nov 11:1-8. doi: 10.1080/10428194.2020.1845340.
    PubMed     Abstract available

  23. GAUT D, Mead M
    Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
    Leuk Lymphoma. 2020 Nov 2:1-24. doi: 10.1080/10428194.2020.1827251.
    PubMed     Abstract available

  24. ABBOUD R, Slade M, Abboud C, DiPersio JF, et al
    Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation?
    Leuk Lymphoma. 2020 Nov 2:1-3. doi: 10.1080/10428194.2020.1839657.

  25. PAN W, Zhao X, Shi W, Jiang Z, et al
    Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020;61:2756-2759.

    October 2020
  26. LIU W, Wu M, Xie Y, Zhang C, et al
    Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 15:1-7. doi: 10.1080/10428194.2020.1834092.
    PubMed     Abstract available

  27. SINGH V, Jang H, Kim S, Ayash L, et al
    G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD.
    Leuk Lymphoma. 2020 Oct 12:1-8. doi: 10.1080/10428194.2020.1827244.
    PubMed     Abstract available

  28. HEINICKE T, Labopin M, Polge E, Stelljes M, et al
    Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.
    Leuk Lymphoma. 2020 Oct 11:1-11. doi: 10.1080/10428194.2020.1827248.
    PubMed     Abstract available

  29. MOUNTJOY L, Palmer J, Kunze KL, Khera N, et al
    Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?
    Leuk Lymphoma. 2020 Oct 4:1-3. doi: 10.1080/10428194.2020.1827249.

    September 2020
  30. LADHA A, Mannis G, Muffly L
    Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.
    Leuk Lymphoma. 2020 Sep 29:1-7. doi: 10.1080/10428194.2020.1827247.
    PubMed     Abstract available

  31. TATARCZUCH M, Paul E, Gilberston M, Gregory GP, et al
    Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.
    Leuk Lymphoma. 2020 Sep 27:1-6. doi: 10.1080/10428194.2020.1821007.
    PubMed     Abstract available

  32. GLOVER A, Fox CP, McMillan A, Beech A, et al
    A comparison of bendamustine-EAM versus BEAM conditioning for autogolous stem cell transplant in lymphoma.
    Leuk Lymphoma. 2020 Sep 8:1-3. doi: 10.1080/10428194.2020.1811863.

  33. KINSELLA FAM, Bencito A, Kulik D, Hurst E, et al
    UK national audit of extracorporeal photopheresis (ECP) in chronic graft versus host disease.
    Leuk Lymphoma. 2020 Sep 2:1-4. doi: 10.1080/10428194.2020.1815015.

    August 2020
  34. HAGEN P, D'Souza A, Hari P, Davila O, et al
    Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.
    Leuk Lymphoma. 2020 Aug 31:1-9. doi: 10.1080/10428194.2020.1811275.
    PubMed     Abstract available

  35. BAI B, Gao Y, Wang XX, He HX, et al
    Identifying high-risk patients with natural killer/T-cell lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2020 Aug 20:1-8. doi: 10.1080/10428194.2020.1808203.
    PubMed     Abstract available

  36. NAGAHATA Y, Kondo T, Ono Y, Hiramoto N, et al
    High-dose cytarabine chemotherapy (>/=4 g/m(2)/day) before allogeneic hematopoietic stem cell transplantation for non-core-binding-factor AML in the first complete remission.
    Leuk Lymphoma. 2020 Aug 17:1-9. doi: 10.1080/10428194.2020.1805112.
    PubMed     Abstract available

  37. MODI D, Kim S, Surapaneni M, Ayash L, et al
    Absolute lymphocyte count on the first day of thymoglobulin predicts relapse-free survival in matched unrelated peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2020 Aug 11:1-9. doi: 10.1080/10428194.2020.1805114.
    PubMed     Abstract available

  38. PRABAHRAN AA, Ritchie DS
    Poor graft function, a significant and emerging clinical challenge post allogeneic stem cell transplantation.
    Leuk Lymphoma. 2020 Aug 7:1-2. doi: 10.1080/10428194.2020.1803301.

    The gift that keeps on giving: lenalidomide maintenance after second autologous stem cell transplant in multiple myeloma.
    Leuk Lymphoma. 2020 Aug 4:1-4. doi: 10.1080/10428194.2020.1798952.

    July 2020
  40. ABUDAYYEH A, Lin H, Mamlouk O, Abdelrahim M, et al
    Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma.
    Leuk Lymphoma. 2020 Jul 29:1-11. doi: 10.1080/10428194.2020.1797719.
    PubMed     Abstract available

  41. REICH-SLOTKY R, Al-Mulla N, Hafez R, Segovia J, et al
    Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant.
    Leuk Lymphoma. 2020 Jul 14:1-6. doi: 10.1080/10428194.2020.1789622.
    PubMed     Abstract available

  42. BROWN M, Abasov R, Salerno D, Shore TB, et al
    Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020 Jul 11:1-3. doi: 10.1080/10428194.2020.1791855.

  43. MARTINEZ C, Boumendil A, Romejko-Jarosinska J, Anagnostopoulos A, et al
    Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT.
    Leuk Lymphoma. 2020 Jul 11:1-8. doi: 10.1080/10428194.2020.1789624.
    PubMed     Abstract available

  44. PARTANEN A, Turunen A, Valtola J, Pyorala M, et al
    Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34(+) cells is associated with improved survival.
    Leuk Lymphoma. 2020 Jul 10:1-3. doi: 10.1080/10428194.2020.1789629.

  45. ZHAO X, Lu X, Tang L, Yan H, et al
    Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Leuk Lymphoma. 2020 Jul 10:1-9. doi: 10.1080/10428194.2020.1789621.
    PubMed     Abstract available

  46. ISUFI I, Seropian S, Gowda L, Wilson LD, et al
    Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.
    Leuk Lymphoma. 2020 Jul 9:1-7. doi: 10.1080/10428194.2020.1790555.
    PubMed     Abstract available

    June 2020
  47. SONG GY, Jung SH, Lee JJ, Kim JS, et al
    Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
    Leuk Lymphoma. 2020 Jun 25:1-8. doi: 10.1080/10428194.2020.1783448.
    PubMed     Abstract available

  48. LU JP, Wang FX, Wen SP, Liu X, et al
    Haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in the treatment of T-lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-4. doi: 10.1080/10428194.2020.1775205.

  49. TANG C, Espin-Garcia O, Prica A, Kurkreti V, et al
    Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Leuk Lymphoma. 2020 Jun 1:1-8. doi: 10.1080/10428194.2020.1762882.
    PubMed     Abstract available

    May 2020
  50. JANSEN L, Merz M, Engelhardt M, Weisel K, et al
    Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects.
    Leuk Lymphoma. 2020 May 30:1-10. doi: 10.1080/10428194.2020.1768383.
    PubMed     Abstract available

  51. ROBINSON DH, Hughes CFM, Grigg A
    Optimal oral cyclosporin dosing with concomitant posaconazole post allogeneic stem cell transplantation.
    Leuk Lymphoma. 2020 May 30:1-5. doi: 10.1080/10428194.2020.1768381.
    PubMed     Abstract available

  52. VARMA A, Loya J, Junaid Hussain M, Don Yun H, et al
    Calcineurin-inhibitor induced pain syndrome after stem cell transplant.
    Leuk Lymphoma. 2020 May 20:1-4. doi: 10.1080/10428194.2020.1765235.

  53. MARCHESI F, Capria S, Pedata M, Terrenato I, et al
    BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
    Leuk Lymphoma. 2020 May 18:1-4. doi: 10.1080/10428194.2020.1765238.

  54. HAN H, Shin DY, Kim D, Kim H, et al
    Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia.
    Leuk Lymphoma. 2020 May 6:1-11. doi: 10.1080/10428194.2020.1747062.
    PubMed     Abstract available

    April 2020
  55. KIM YE, Kim H, Shin J, Min SY, et al
    Stage IV natural killer/T-cell lymphoma with chronic active Epstein-Barr virus, treated with pembrolizumab and TCRalphabeta-depleted haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020 Apr 30:1-4. doi: 10.1080/10428194.2020.1757666.

  56. MODI D, Chi J, Kim S, Ayash L, et al
    Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.
    Leuk Lymphoma. 2020 Apr 9:1-8. doi: 10.1080/10428194.2020.1749603.
    PubMed     Abstract available

    March 2020
  57. RODRIGUEZ-LOBATO LG, Martinez-Roca A, Moreno DF, Gutierrez-Garcia G, et al
    Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients.
    Leuk Lymphoma. 2020 Mar 25:1-10. doi: 10.1080/10428194.2020.1742901.
    PubMed     Abstract available

  58. BENTOLILA G, Pavlovsky A
    Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation.
    Leuk Lymphoma. 2020 Mar 9:1-7. doi: 10.1080/10428194.2020.1732959.
    PubMed     Abstract available

    February 2020
  59. PWINT KW, Chen Y, Diong CP, Goh YT, et al
    Mobilization kinetics of peripheral blood stem cells with rescue plerixafor - real-world experience from a single center.
    Leuk Lymphoma. 2020 Feb 24:1-4. doi: 10.1080/10428194.2020.1731501.

  60. KORT J, Chidiac A, El Sayed R, Massoud R, et al
    Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Feb 22:1-4. doi: 10.1080/10428194.2020.1728755.
    PubMed     Abstract available

  61. ORFALI N, van Besien K
    Combining haplo-identical and cord blood stem cell grafts - might the whole be greater than the sum of its parts?
    Leuk Lymphoma. 2020 Feb 12:1-4. doi: 10.1080/10428194.2020.1725509.

  62. NARAZAKI T, Shiratsuchi M, Matsushima T, Tsuda M, et al
    Clinico-pathological characteristics of primary adrenal lymphomas - potential efficacy of autologous stem cell transplantation.
    Leuk Lymphoma. 2020 Feb 10:1-3. doi: 10.1080/10428194.2020.1725507.

  63. HAZAR V, Karasu GT, Uygun V, Ozbek N, et al
    Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the Turkish Bone Marrow Transplantation Study Group.
    Leuk Lymphoma. 2020 Feb 8:1-10. doi: 10.1080/10428194.2020.1716220.
    PubMed     Abstract available

  64. ABBASI S, Britt A, McClune B, Shune L, et al
    Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample.
    Leuk Lymphoma. 2020 Feb 7:1-3. doi: 10.1080/10428194.2020.1719094.

    January 2020
  65. SHAH S, Martin A, Turner M, Cong Z, et al
    A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease.
    Leuk Lymphoma. 2020 Jan 21:1-11. doi: 10.1080/10428194.2019.1709834.
    PubMed     Abstract available

  66. ZINZANI PL, Chen R, Armand P, Johnson NA, et al
    Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.
    Leuk Lymphoma. 2020 Jan 6:1-5. doi: 10.1080/10428194.2019.1702178.

    December 2019
  67. ITO M, Yagasaki H, Nakahara E, Okuma H, et al
    Haploidentical bone marrow transplantation in a child with fatal hepatic failure due to graft-versus-host disease after cord blood transplantation.
    Leuk Lymphoma. 2019 Dec 26:1-2. doi: 10.1080/10428194.2019.1706730.

    November 2019
  68. LYU H, Lu W, Yao J, Xiao X, et al
    Comparison of outcomes of haploidentical donor hematopoietic stem cell transplantation supported by third-party cord blood with HLA-matched unrelated donor transplantation.
    Leuk Lymphoma. 2019 Nov 28:1-8. doi: 10.1080/10428194.2019.1695053.
    PubMed     Abstract available

  69. CHHABRA S, Jerkins JH, Conto JE, Zellner K, et al
    Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease.
    Leuk Lymphoma. 2019 Nov 25:1-6. doi: 10.1080/10428194.2019.1695049.
    PubMed     Abstract available

  70. SHIMOMURA Y, Hara M, Maruoka H, Yabushita T, et al
    Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2019 Nov 11:1-4. doi: 10.1080/10428194.2019.1686500.

    October 2019
  71. BATOROV EV, Pronkina NV, Tikhonova MA, Kryuchkova IV, et al
    Increased circulating CD3(+) T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma.
    Leuk Lymphoma. 2019;60:2488-2497.
    PubMed     Abstract available

    September 2019
    Lymphoblastic leukemia following MDS or MDS/MPN: clinical evidence for stem cell origins of these disorders.
    Leuk Lymphoma. 2019 Sep 26:1-2. doi: 10.1080/10428194.2019.1666382.

  73. NGUYEN TM, Scholl K, Idler I, Wais V, et al
    Granulocyte transfusions - bridging to allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2019 Sep 24:1-4. doi: 10.1080/10428194.2019.1660977.

  74. WANG F, Liu T, Wang L, Gu Z, et al
    Unmanipulated haploidentical peripheral blood stem cell transplantation for patients with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission.
    Leuk Lymphoma. 2019 Sep 13:1-10. doi: 10.1080/10428194.2019.1660965.
    PubMed     Abstract available

  75. JOSHI M, Taper J, Forsyth C, Rowlings P, et al
    Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.
    Leuk Lymphoma. 2019 Sep 12:1-7. doi: 10.1080/10428194.2019.1660968.
    PubMed     Abstract available

  76. NAGAI Y, Tsukamoto S, Hino Y, Isshiki Y, et al
    Remarkable donor-derived T cell lymphocytosis before engraftment of a bone marrow transplant for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 5:1-4. doi: 10.1080/10428194.2019.1660973.

  77. MANCONI L, Coviello E, Canale F, Giannoni L, et al
    Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.
    Leuk Lymphoma. 2019 Sep 4:1-7. doi: 10.1080/10428194.2019.1658102.
    PubMed     Abstract available

    August 2019
  78. BALDUCCI E, Sanekli S, Hugues P, Soubeyrand M, et al
    Co-occurrence of BCR-ABL1 rearrangement and CALR mutation in a single leukemic stem cell: evidence that BCR-ABL1 oncogenic addiction prevails over CALR signaling.
    Leuk Lymphoma. 2019 Aug 29:1-4. doi: 10.1080/10428194.2019.1658101.

  79. XIAO Z, Acuna-Villaorduna A, Mantzaris I
    Brachial plexopathy following autologous hematopoietic stem cell transplant: an unrecognized complication of autologous transplantation.
    Leuk Lymphoma. 2019 Aug 20:1-3. doi: 10.1080/10428194.2019.1654094.

  80. BLOCKA J, Hielscher T, Mueller-Tidow C, Goldschmidt H, et al
    Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy.
    Leuk Lymphoma. 2019 Aug 19:1-10. doi: 10.1080/10428194.2019.1646905.
    PubMed     Abstract available

  81. MCILROY G, Nikolousis E, Abou-Zeid N, Shankara P, et al
    Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2019 Aug 11:1-4. doi: 10.1080/10428194.2019.1650177.

  82. WONG E, Davis J, Koldej R, Szer J, et al
    Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2019 Aug 7:1-4. doi: 10.1080/10428194.2019.1648803.

    July 2019
  83. KNORR DA, Goldberg AD, Stein EM, Tallman MS, et al
    Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.
    Leuk Lymphoma. 2019 Jul 23:1-13. doi: 10.1080/10428194.2019.1639167.
    PubMed     Abstract available

  84. YAMAGUCHI J, Chinen Y, Takimoto-Shimomura T, Nagata H, et al
    Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Jul 18:1-8. doi: 10.1080/10428194.2019.1636982.
    PubMed     Abstract available

  85. STRUNZ PP, Schmalzing M, Heidemeier A, Rasche L, et al
    Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor.
    Leuk Lymphoma. 2019 Jul 18:1-4. doi: 10.1080/10428194.2019.1636981.

  86. HARADA K, Tachibana T, Ohashi K, Ozawa Y, et al
    The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation.
    Leuk Lymphoma. 2019 Jul 10:1-8. doi: 10.1080/10428194.2019.1636986.
    PubMed     Abstract available

    June 2019
  87. OKAMURA-SHIKI I, Moriguchi M, Uehara T, Fukaya M, et al
    Levothyroxine tablet (Thyradin-S)-induced autoimmune-like hepatitis following post-transplant Hashimoto's thyroiditis in a patient after allogenic bone marrow transplantation.
    Leuk Lymphoma. 2019 Jun 17:1-3. doi: 10.1080/10428194.2018.1563695.

    May 2019
  88. SHIMAZU Y, Nohgawa M
    Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma.
    Leuk Lymphoma. 2019 May 20:1-2. doi: 10.1080/10428194.2019.1616188.

  89. HORGAN C, Elmoamly S, McIlroy G, Davies D, et al
    Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
    Leuk Lymphoma. 2019 May 13:1-3. doi: 10.1080/10428194.2019.1607323.

    April 2019
  90. GARCIAZ S, Loschi M, De Masson A, Biard L, et al
    Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
    Leuk Lymphoma. 2019 Apr 24:1-4. doi: 10.1080/10428194.2019.1599112.

  91. TOTH LN, Green D, Peterson J, Deharvengt SJ, et al
    Variant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup.
    Leuk Lymphoma. 2019 Apr 18:1-8. doi: 10.1080/10428194.2019.1587757.
    PubMed     Abstract available

  92. XU M, Liu H, Liu Y, Ma X, et al
    Gene mutations and pretransplant minimal residual disease predict risk of relapse in adult patients after allogeneic hematopoietic stem-cell transplantation for T cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 5:1-10. doi: 10.1080/10428194.2019.1597270.
    PubMed     Abstract available

  93. BEYAR-KATZ O, Lavi N, Ringelstein-Harlev S, Henig I, et al
    Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594214.
    PubMed     Abstract available

  94. SHALLIS RM, Gleeson S, Azar M, Malinis M, et al
    Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations.
    Leuk Lymphoma. 2019 Apr 3:1-4. doi: 10.1080/10428194.2019.1594221.

    March 2019
  95. CHO SK, McCombs J, Punwani N, Lam J, et al
    Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States.
    Leuk Lymphoma. 2019 Mar 8:1-7. doi: 10.1080/10428194.2019.1581932.
    PubMed     Abstract available

  96. DOSANI T, Covut F, Pinto R, Kim BG, et al
    Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.
    Leuk Lymphoma. 2019 Mar 7:1-8. doi: 10.1080/10428194.2019.1573367.
    PubMed     Abstract available

    February 2019
  97. HORVATH N, Spencer A, Kenealy M, Joshua D, et al
    Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.
    Leuk Lymphoma. 2019 Feb 19:1-12. doi: 10.1080/10428194.2019.1579322.
    PubMed     Abstract available

  98. YUCEBAY F, Matthews C, Puto M, Li J, et al
    Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
    Leuk Lymphoma. 2019 Feb 15:1-7. doi: 10.1080/10428194.2019.1573996.
    PubMed     Abstract available

  99. OKA S, Ono K, Nohgawa M
    Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation.
    Leuk Lymphoma. 2019 Feb 8:1-3. doi: 10.1080/10428194.2018.1537489.

    January 2019
  100. SALLES GA, Pettengell R, Cordoba R, Dlugosz-Danecka M, et al
    Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review.
    Leuk Lymphoma. 2019 Jan 31:1-16. doi: 10.1080/10428194.2018.1564828.
    PubMed     Abstract available

  101. SHIPOUNOVA IN, Petinati NA, Bigildeev AE, Sorokina TV, et al
    Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1554861.
    PubMed     Abstract available

  102. CHRISTEN D, Sohlbach K, Metzelder SK, Wollmer E, et al
    Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation.
    Leuk Lymphoma. 2019 Jan 15:1-6. doi: 10.1080/10428194.2018.1553303.
    PubMed     Abstract available

  103. KREFT A, Neumann H, Schindeldecker M, Wagner-Drouet EM, et al
    Diagnosis and grading of acute graft-versus-host disease in endoscopic biopsy series throughout the upper and lower intestine in patients after allogenic hematopoietic stem cell transplantation: a systematic approach.
    Leuk Lymphoma. 2019 Jan 11:1-10. doi: 10.1080/10428194.2018.1535118.
    PubMed     Abstract available

  104. JAIN T, Kunze KL, Khetarpal BK, McCallen MR, et al
    Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?
    Leuk Lymphoma. 2019 Jan 10:1-8. doi: 10.1080/10428194.2018.1562183.
    PubMed     Abstract available

  105. KOSMAS C, Kranidioti E, Kosma A, Karakosta M, et al
    Re-mobilization of hematopoietic progenitors for further autografting after prior myelo-ablative high-dose chemotherapy and autologous hematopoietic stem cell transplantation; the role of plerixafor.
    Leuk Lymphoma. 2019 Jan 8:1-4. doi: 10.1080/10428194.2018.1543879.

    December 2018
  106. OCK CY, Seo H, Kim DY, Min BJ, et al
    Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Dec 3:1-7. doi: 10.1080/10428194.2018.1542142.
    PubMed     Abstract available

    November 2018
  107. HARADA K, Yanada M, Machida S, Kanamori H, et al
    Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning.
    Leuk Lymphoma. 2018 Nov 20:1-10. doi: 10.1080/10428194.2018.1535115.
    PubMed     Abstract available

  108. VAN MOURIK A, Grigg A
    Cerebral toxoplasmosis in a patient with prolonged CD4 lymphopenia post autologous hemopoietic stem cell transplant.
    Leuk Lymphoma. 2018 Nov 8:1-3. doi: 10.1080/10428194.2018.1485906.

    October 2018
  109. TAY J, Vij R, Norkin M, Buadi F, et al
    Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales.
    Leuk Lymphoma. 2018 Oct 31:1-8. doi: 10.1080/10428194.2018.1523399.
    PubMed     Abstract available

  110. SELICEAN SE, Tomuleasa C, Grewal R, Almeida-Porada G, et al
    Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1516881.
    PubMed     Abstract available

    September 2018
  111. HECKL BC, Carlet M, Vick B, Roolf C, et al
    Frequent and reliable engraftment of certain adult primary acute lymphoblastic leukemias in mice.
    Leuk Lymphoma. 2018 Sep 20:1-4. doi: 10.1080/10428194.2018.1509314.

  112. SAHASRABUDHE K, Otto M, Hematti P, Kenkre V, et al
    TCR alphabeta+/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data.
    Leuk Lymphoma. 2018 Sep 6:1-12. doi: 10.1080/10428194.2018.1485905.
    PubMed     Abstract available

  113. MAZHARUDDIN S, Chattopadhyay A, Levy MY, Redner RL, et al
    IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.
    Leuk Lymphoma. 2018;59:2246-2249.

  114. TANG H, Shu M, Dai B, Xu L, et al
    DNA damage response-initiated cytokine secretion in bone marrow stromal cells promotes chemoresistance of myeloma cells.
    Leuk Lymphoma. 2018;59:2220-2226.
    PubMed     Abstract available

    August 2018
  115. MURNER CM, Stenner-Liewen F, Seifert B, Mueller NJ, et al
    Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation.
    Leuk Lymphoma. 2018 Aug 21:1-11. doi: 10.1080/10428194.2018.1496332.
    PubMed     Abstract available

  116. DELSING MALMBERG E, Johansson Alm S, Nicklasson M, Lazarevic V, et al
    Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
    Leuk Lymphoma. 2018 Aug 2:1-9. doi: 10.1080/10428194.2018.1485910.
    PubMed     Abstract available

    July 2018
  117. KAMEL AM, El-Fishawi S, Rasekh EO, Radwan ER, et al
    Variability of contribution of vitamin D receptor gene polymorphisms to outcome of HLA-matched sibling allogeneic bone marrow transplantation.
    Leuk Lymphoma. 2018 Jul 4:1-10. doi: 10.1080/10428194.2018.1459608.
    PubMed     Abstract available

  118. ADRIANZEN HERRERA D, Ayyappan S, Jasra S, Kornblum N, et al
    Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant - a case series.
    Leuk Lymphoma. 2018 Jul 3:1-7. doi: 10.1080/10428194.2018.1474523.
    PubMed     Abstract available

  119. ROMERO S, Montoro J, Guinot M, Almenar L, et al
    Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1474462.
    PubMed     Abstract available

  120. PONTIKOGLOU C, Kalyva A, Kalpadakis C, Velegraki M, et al
    Bone marrow-derived mesenchymal stem/stromal cells from patients with splenic marginal zone lymphoma are intrinsically impaired and influence the malignant B-cells.
    Leuk Lymphoma. 2018 Jul 3:1-3. doi: 10.1080/10428194.2018.1474526.

  121. CUMMINS KD, Gill S
    Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
    Leuk Lymphoma. 2018;59:1539-1553.
    PubMed     Abstract available

    June 2018
  122. PERMPALUNG N, Mahoney MV, McCoy C, Atsawarungruangkit A, et al
    Clinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving palivizumab.
    Leuk Lymphoma. 2018 Jun 27:1-7. doi: 10.1080/10428194.2018.1468896.
    PubMed     Abstract available

  123. CAPRIA S, Pepe S, Trisolini SM, Testi AM, et al
    Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease.
    Leuk Lymphoma. 2018 Jun 26:1-3. doi: 10.1080/10428194.2018.1468895.

  124. PODSZYWALOW-BARTNICKA P, Maifrede S, Le BV, Nieborowska-Skorska M, et al
    PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.
    Leuk Lymphoma. 2018 Jun 22:1-3. doi: 10.1080/10428194.2018.1471602.

    May 2018
  125. REICH-SLOTKY R, Makhani SS, Vasovic LV, Pearse RN, et al
    Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products.
    Leuk Lymphoma. 2018 May 23:1-7. doi: 10.1080/10428194.2018.1455975.
    PubMed     Abstract available

  126. ALDERUCCIO JP, Mackrides N, Chapman JR, Vega F, et al
    Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome.
    Leuk Lymphoma. 2018 May 10:1-4. doi: 10.1080/10428194.2018.1461862.

  127. MORI Y, Yoshimoto G, Yuda JI, Hayashi M, et al
    Previous exposure to bortezomib is linked to a lower risk of engraftment syndrome after autologous hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 May 9:1-3. doi: 10.1080/10428194.2018.1466295.

  128. SPINA F, Radice T, De Philippis C, Soldarini M, et al
    Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
    Leuk Lymphoma. 2018 May 1:1-9. doi: 10.1080/10428194.2018.1459607.
    PubMed     Abstract available

    April 2018
  129. KOBULNICKY DJ, Sabo RT, Sharma S, Shubar Ali AS, et al
    The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-9. doi: 10.1080/10428194.2018.1452216.
    PubMed     Abstract available

  130. KUROSAWA S, Toya T, Kishida Y, Nagata A, et al
    Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1441410.

  131. KJAER L, Holmstrom MO, Cordua S, Andersen MH, et al
    Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.
    Leuk Lymphoma. 2018;59:973-977.

    March 2018
  132. ANDREINI A, Zampieri N, Costantini C, Malerba G, et al
    Chronic graft versus host disease is associated with erectile dysfunction in allogeneic hematopoietic stem cell transplant patients: a single-center experience.
    Leuk Lymphoma. 2018 Mar 21:1-4. doi: 10.1080/10428194.2018.1443338.

  133. POLVERELLI N, Malagola M, Turra A, Skert C, et al
    Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years.
    Leuk Lymphoma. 2018 Mar 12:1-6. doi: 10.1080/10428194.2018.1439584.

    February 2018
  134. KARANTANOU C, Godavarthy PS, Krause DS
    Targeting the bone marrow microenvironment in acute leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434886.
    PubMed     Abstract available

  135. ICHII M, Oritani K, Murase M, Komatsu K, et al
    Molecular targeting of inosine-5'-monophosphate dehydrogenase by FF-10501 promotes erythropoiesis via ROS/MAPK pathway.
    Leuk Lymphoma. 2018;59:448-459.
    PubMed     Abstract available

    January 2018
  136. CAO L, Koh LP, Linn YC
    Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib.
    Leuk Lymphoma. 2018 Jan 18:1-3. doi: 10.1080/10428194.2017.1421759.

  137. BLUME R, Rempel E, Manta L, Saeed BR, et al
    The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
    Leuk Lymphoma. 2018 Jan 16:1-10. doi: 10.1080/10428194.2017.1422862.
    PubMed     Abstract available

  138. CUI J, Zhu Z, Liu S, Li Q, et al
    Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jan 16:1-3. doi: 10.1080/10428194.2017.1421755.

  139. COSIMATO V, Scalia G, Raia M, Gentile L, et al
    Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients.
    Leuk Lymphoma. 2018 Jan 15:1-4. doi: 10.1080/10428194.2017.1416366.

  140. CHEN A, Chao K, Rodriguez L, Munday W, et al
    Toxic epidermal necrolysis versus cutaneous Graft-Versus-Host Disease in a hematopoietic stem cell transplant recipient: the role of elafin.
    Leuk Lymphoma. 2018 Jan 11:1-3. doi: 10.1080/10428194.2017.1422867.

    December 2017
  141. YABUSHITA T, Satake H, Maruoka H, Morita M, et al
    Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-8. doi: 10.1080/10428194.2017.1410888.
    PubMed     Abstract available

  142. TANDRA A, Covut F, Cooper B, Creger R, et al
    Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.
    Leuk Lymphoma. 2017 Dec 4:1-8. doi: 10.1080/10428194.2017.1390234.
    PubMed     Abstract available

    November 2017
  143. GIULINO-ROTH L, O'Donohue T, Chen Z, Trippett TM, et al
    Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.
    Leuk Lymphoma. 2017 Nov 29:1-10. doi: 10.1080/10428194.2017.1403601.
    PubMed     Abstract available

  144. SASAKI K, Mori Y, Yoshimoto G, Sakoda T, et al
    Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation.
    Leuk Lymphoma. 2017 Nov 22:1-3. doi: 10.1080/10428194.2017.1403021.

    October 2017
  145. STEVENS H, Raj K, Ashby M, Grigg A, et al
    Allogeneic stem cell transplantation as a risk factor for recurrent melanoma.
    Leuk Lymphoma. 2017 Oct 31:1-3. doi: 10.1080/10428194.2017.1393670.

  146. GREIL C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, et al
    Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1393673.

  147. PATEL P, Oh AL, Koshy M, Sweiss K, et al
    A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.
    Leuk Lymphoma. 2017 Oct 25:1-6. doi: 10.1080/10428194.2017.1390231.
    PubMed     Abstract available

  148. ZAGADAILOV EA, Corman S, Chirikov V, Johnson C, et al
    Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1382698.
    PubMed     Abstract available

  149. PENG L, Tang Y, Zhang Y, Guo S, et al
    Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-8. doi: 10.1080/10428194.2017.1387906.
    PubMed     Abstract available

  150. LI WY, Wang Y, Chen SN, Qiu HY, et al
    Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1390235.
    PubMed     Abstract available

  151. MOTOHASHI K, Fujisawa S, Doki N, Kobayashi T, et al
    Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2017 Oct 16:1-6. doi: 10.1080/10428194.2017.1387913.
    PubMed     Abstract available

  152. VANGAPANDU HV, Chen H, Wierda WG, Keating MJ, et al
    Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.
    Leuk Lymphoma. 2017 Oct 3:1-12. doi: 10.1080/10428194.2017.1376747.
    PubMed     Abstract available

    September 2017
  153. ZINTER MS, Melton A, Sabnis AJ, Dvorak CC, et al
    Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.
    Leuk Lymphoma. 2017 Sep 28:1-4. doi: 10.1080/10428194.2017.1382697.

  154. MAZIARZ RT, Hao Y, Guerin A, Gauthier G, et al
    Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 21:1-10. doi: 10.1080/10428194.2017.1375100.
    PubMed     Abstract available

    June 2017
  155. NASILLO V, Paolini A, Riva G, Morselli M, et al
    Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2017 Jun 7:1-4. doi: 10.1080/10428194.2017.1321748.

    May 2017
  156. OKABE S, Tauchi T, Tanaka Y, Ohyashiki K, et al
    Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.
    Leuk Lymphoma. 2017 May 15:1-3. doi: 10.1080/10428194.2017.1312373.

    January 2017
  157. PETERSON LF, Lo MC, Liu Y, Gianolla D, et al
    Induction of p53 suppresses chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jan 13:1-14. doi: 10.1080/10428194.2016.1272682.
    PubMed     Abstract available

  158. ISHII H, Konuma T, Kato S, Oiwa-Monna M, et al
    Impact of hematogones on the long-term outcomes of single-unit cord blood transplantation for adult patients.
    Leuk Lymphoma. 2017;58:118-126.
    PubMed     Abstract available

    March 2016
  159. BELTON A, Xian L, Huso T, Koo M, et al
    STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.
    Leuk Lymphoma. 2016.

    January 2016
  160. VALTOLA J, Varmavuo V, Ropponen A, Selander T, et al
    Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance.
    Leuk Lymphoma. 2016.
    PubMed     Abstract available

  161. SANFORD D, Garcia-Manero G, Jorgensen J, Konoplev S, et al
    CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count.
    Leuk Lymphoma. 2016.

    December 2015
  162. GARG S, Shanmukhaiah C, Ghosh K, Madkaikar M, et al
    Cell signaling in putative leukemic stem cells and blast population in acute myeloid leukemia.
    Leuk Lymphoma. 2015.

Thank you for your interest in scientific medicine.

AMEDEO Stem Cell Research is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.